Scilex Holding Company Write off of Deferred Debt Issuance Cost
Scilex Holding Company (SCLX) reported Write off of Deferred Debt Issuance Cost of $17.30 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:WriteOffOfDeferredDebtIssuanceCost · last filed 2025-03-31
- Scilex Holding Company write off of deferred debt issuance cost for the quarter ending 2024-12-31 was $14.77M.
- Scilex Holding Company write off of deferred debt issuance cost for the quarter ending 2024-09-30 was $0.00.
- Scilex Holding Company write off of deferred debt issuance cost for the quarter ending 2024-06-30 was $1.15M.
- Scilex Holding Company write off of deferred debt issuance cost for the quarter ending 2024-03-31 was $1.38M.
- Scilex Holding Company write off of deferred debt issuance cost for fiscal 2024 was $17.30M.
- Scilex Holding Company write off of deferred debt issuance cost for fiscal 2023 was $0.00.
| Period end | Write off of Deferred Debt Issuance Cost 3 month | Write off of Deferred Debt Issuance Cost 6 month | Write off of Deferred Debt Issuance Cost 9 month | Write off of Deferred Debt Issuance Cost 12 month |
|---|---|---|---|---|
| 2024-12-31 | $14.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $14.77M derived: sum of 2 quarters · filed 2025-03-31 | $15.92M derived: sum of 3 quarters · filed 2025-03-31 | $17.30M 10-K · filed 2025-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | $1.15M derived: sum of 2 quarters · filed 2025-01-17 | $2.53M 10-Q · filed 2025-01-17 | $2.53M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.53M 10-Q · filed 2024-08-13 | $2.53M derived: sum of 3 quarters · filed 2025-03-31 | $2.53M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | $1.38M 10-Q · filed 2024-05-13 | $1.38M derived: sum of 2 quarters · filed 2025-03-31 | $1.38M derived: sum of 3 quarters · filed 2025-03-31 | $1.38M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | $0.00 derived: sum of 2 quarters · filed 2025-01-17 | $0.00 10-Q · filed 2025-01-17 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |